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(From the Department ofPathology, Harvard Medical School, Boston, Massachusetts 02115)
After appropriate in vivo or in vitro immunization, cytotoxic T lymphocytes
(CTL) are generated which efficiently kill cells bearing particular membrane
antigens in common with the immunizing cell (reviewed in reference 1) . Such
CTL have been most thoroughly studied in mice, employing alloimmunization
with cells differing at the major histocompatibility locus, H-2 . In such cases, the
predominant cell surface antigens recognized by the CTL appear to be the
molecules carrying the serologically defined H-2 specificities, coded for by theK
andD regions of the H-2 complex (2) . In other syngeneic models of cell-mediated
specific cytolysis, involving lymphocyte choriomeningitis (LCM) virus- or ectro-
melia virus-infected cells or TNP-modified lymphoid cells, thymus-derived cells
also constitute the main effector cell type . The CTL generated in these latter
systems function most efficiently when virus-infected or TNP-modified target
cells share identities at the H-2K or H-2D loci with the effector CTL and
stimulator cells (3-5) .
Another set of experimental systems in which CTL are generated and play a
significant biological role is that of immunity to tumor-associated antigens
(TAA) (6) . The nature of the TAA which the CTL recognize is only beginning to
be understood . Several recent reports indicated the existence of physiochemical
and/or antigenic relationships between TAA and H-2 antigens (7, 8) . These
relationships, together with the genetic restrictions cited above in the genera-
tion ofCTL involving products of theH-2K orH-2D loci suggested the possibility
that in certain tumor systems, the TAA which are able to most effectively
stimulate CTL responses might be structurally similar to, or linked with, the H-
2K or H-2D molecules on the tumor surface . It has been previously demon-
strated in allogeneicmodels that antisera specific for the appropriate H-2K or H-
2D products present on a target cell could specifically block CTL-mediated lysis
(1, 9) . This report demonstrates that certain anti-H-2 alloantisera specific for the
target tumor cells can block lysis of those target cells mediated by syngeneic
tumor-specific CTL effector cells .
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Materials and Methods
Mice .
￿
The mice used in this studywere DBA/2, (C57BL/6 x DBA/2)F,, referred to as (B6D2)F,,
or (C3H/HeJ x DBA/2)F,, referred to as (C3D2)F,, females 8- to 14-wk old, purchasedfrom Jackson
Laboratories, Bar Harbor, Maine.
Tumors .
￿
The two tumors (P815 and SL2) used in this study were of DBA/2 origin . The P815
mastocytomainduced by methylocholanthrene andtheSL2lymphoma, whicharosespontaneously
were passaged intraperitoneally (i.p .) in ascites form at biweekly intervals in DBA/2 mice .
Antisera .
￿
Alloantisera were prepared by giving mice 4-8 i.p . injections of 2 x 10' viable P815
or appropriate lymphocytes at 2-wk intervals and bleeding 6 to 10 days after the last injection .
Sera were pooled, heat inactivated at 56°C for 30 min and stored at -70°C until use. The donor-
recipient combinations used and the specificity of each serum is listed in Table 1 . 0.45 ml of B10
anti-P815was absorbed with 4 aliquots of 10 x 10'spleen cells from C57BL/10 or B10.D2 mice by
incubating each time for 15 min at room temperature, and 45 min at 4°C.
Media.
￿
RPMI-1640 was purchasedfrom Associated Biomedic Systems, Inc., Buffalo, N.Y . The
medium used in the cytolysis assays was termed minimal essential medium (SMEM)-10 and
contains Eagle's MEM with Earle's balanced salt solution (BSS) with 2 mM glutamine, 1 x
nonessential amino acids, 100U penicillin/ml, 100 wg streptomycin/ml, and 10% heat-inactivated
fetal calf serum (Microbiological Associates, Bethesda, Md.) .
Immunization and Preparation of Effector Cells .
￿
Inguinal lymph nodes draining the site of
subcutaneous (s .c .) tumor growth 10 days after tumor inoculation were teased, filtered through
nylon mesh, washed four times, and resuspended in cold SMEM-10 to 30 x 106 viable cells/ml .
Normal lymph node or splenic lymphocytes were similarly prepared .
"Cr Release Assay.
￿
The method of preparing and ''Cr-labeling target tumor cells has been
reported previously (10) . 100 gl of labeled targets containing 15 x 103 cells were placed in 10 x 75
mm round bottom glass tubes, 50 pl of SMEM-10, 1:2 dilutions of normal mouse serum (NMS) or
alloantiserum in SMEM-10 added, andthetubesshaken . After 15 min at room temperature, 100 WI
of immune or normal lymphocytes were added, thetubes shaken, and incubated for 18 h at 37'C in
ahumid atmosphere of 95% air, 5%CO z. Determination ofspecific "Cr releasein theseassaytubes
was carried out as described (10) . Final effector to target ratio in all assays was 200 :1, and final
NMS or antiserum dilution 1 :10 unless otherwise indicated .
Results
Previous results from our laboratory have demonstrated that CTL are the
primary effector cell in preparations from the draining lymph nodes of DBA/2,
(C3D2)F 1 , and (B6D2)F, mice bearing syngeneic 10 days s.c . P815 or SL2 tumors .
Fig . 1 illustrates results obtained in several experiments in which antisera were
tested for inhibition of CTL-mediated tumor lysis. The data show strong (30-
50%) decreases in lysis using either the B10 anti-P815 serum or serum no . 438
(anti-H-21)') for inhibition of cytolysis of either P815 or SL2 H-2`' tumors . In
addition, the lack of inhibition seen when (C3D2)F, cells, which carry both the
H-2d andH-2'` haplotypes, are used as effectors in the presence of antibody to the
effector H-2' specificities indicates that antibodies directed only at effector cell
H-2 determinants are unable to prevent target cell lysis . The activity of the
congeneic serum no . 438 (anti-H-21)') demonstrates that inhibition can be
mediated by sera reacting solely with antigens coded for or controlled by the H-2
complex ofnormal lymphoid cells. Fig . 1 also demonstrates that not all alloanti-
sera to H-2 antigens on the tumor cell surface are able to strongly inhibit CTL
activity . Thus, antiserum no . 329 (anti-H-2K') showed an inconsistent ability to
provide marginal blocking of SL2 tumor cell lysis, even though titrations of
complement-dependent lytic activity using this tumor antiserum combination
show significant H-2K' antigen on these tumor cells .GERMAIN ET AL .
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FIG . 1 .
￿
Ability of various anti-H-2° alloantisera to inhibit tumor-specific CTL-mediated
lysis of P815 or SL2 . P values are given for each antisera in comparison to NMS.
FIG . 2 .
￿
Ability of B10 anti-P815 serum to inhibit tumor-specific lysis before absorption and
after absorption with B10 or B10.D2 lymphocytes . Pvalues are given for each antiserum in
comparison to NMS.
These results are extended in the data show in Fig . 2 . An aliquot of the B10
anti-P815 serum was absorbed with B10.D2 spleen cells to selectively remove
antibodies directed to antigens controlled by the H2 d haplotype . The B10.D2
absorbed antiserum was completely unable to inhibit lysis.
Table I summarizes the ability of a large series of alloantisera to inhibit
tumor-specific CTL activity in this system . It can be seen that antisera directed
to at least the H-21)1-coded specificities are able to mediate strong, consistent
inhibition (Table I) . Antisera specific for antigens controlled by otherportions of
theH2 region or closely linked loci such as Tla are only weakly and inconsist-1026
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TABLE I
Ability of Various Alloantisera to Inhibit CTL-Mediated Tumor Cell Lysis
The recipient/donor combinations used to prepare the antisera were : no. 001 AKR anti-C3H thymus, no . 082
(Bl0.D2 x A.Ca)F, anti-1110, no. 329 (1110 x A)F, anti-Bl0.D2, no . 423 (1110 x A)F, anti-B10.BRm,no. 426 (1110 x
LP.RRI)F, anti-4R, no . 428 A.Tla - anti-A thymus, no . 438 B10 x LP.RIII)F, anti-18R, and no . 445 A.TH anti-
A.TL .
-, no inhibition compared toNMS; -, slight inconsistent inhibition compared toNMS; +, modest consistent
inhibition compared to NMS; and ++, strong consistent inhibition compared to NMS.
$ See Materials and Methods .
ently active, and certain batches of NMS yield similar inconsistent weak pat-
terns of inhibition .
In data not shown, experiments were performedin whichalloantisera directed
to non-CTL recognized H-2 antigens on hybrid target cells were tested for
inhibitory activity . CTL from C57BL/6 (H-2") mice immunized 10 days previ-
ously with an i.p . injection of 2 x 10' P815 (H-2') were tested in the "Cr-release
assay using (B6D2)F' lymph node cells as targets . In the presence of anti-H-21)d
antiserum, lysis was significantly inhibited, while the addition ofa strong anti-
H-2' antiserum did not affect lysis .
Discussion
The data reported above unequivocally demonstrate that lysis of tumor tar-
gets (P815 and SL2) by syngeneic CTL can be inhibited to a large extent by
alloantisera directed to antigens codedfor by certain regions of theH-2 complex .
The inhibitory activity of such sera is not due to antibodies elicited specifically
by the TAA of the P815 or SL2 tumor cells since : (a) antisera raised by
immunization with normal lymphoid cells is inhibitory ; (b) absorption of anti-
sera raised by alloimmunization with P815 so as toremove only antibodies to H-
2-regulated antigens on normal cells removes all inhibitory activity ; and (c)
alloantisera to the P815 mastocytoma can inhibit specific syngeneic killing of
Effector Target Antisera Inhibition ofspecific
cytolysis
DBA/2 P815 B10-anti-P815 +'
DBA/2 P815 No . 438-anti-H-2Dd +
DBA/2 P815 No . 329-anti-H-2Kd -
DBA/2 P815 No . 426-anti-H-2K" -
DBA/2 SL2 B10-anti-P815 ++
DBA/2 SL2 B10-anti-P815 : abs . with B10$ ++
DBA/2 SL2 1110-anti-P815 : abs . with B10.D2* -
DBA/2 SL2 No . 438-anti-H-2Dd ++
DBA/2 SL2 No . 423-anti-H-2D" -
DBA/2 SL2 No . 426-anti-H-2K" -
DBA/2 SL2 No . 001-anti-Thy 1.2 -
(C3D2)F, SL2 B10-anti-P815 ++
(C3D2)F, SL2 No . 438-anti-H-2Dd ++
(C3D2)F, SL2 No . 426-anti-H-2K" -
(C3D2)F, SL2 No . 423-anti-H-2D" -
(C3D2)F, SL2 No . 445-anti-la' -
(C3D2)F, SL2 No . 428-anti-Tla _
(C3D2)F, SL2 No . 329-anti-H-2K" _
(B6D2)F, P815 No . 438-anti-H-2D" +
(B6D2)F, P815 No . 082-anti-H-2K"D" -GERMAIN ET AL .
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the noncross-reactive SL2 tumor cells . In addition, the antisera apparently
mediated their effects by action on the target cell surface, and not by action on
the CTL itself. Finally, not all alloantisera, or even all antisera to target-borne
H-2 specificities, are able to inhibit CTL activity, although the possibility that
other anti-H-2 sera might show strong effects if of sufficient high titer has not
been completely excluded .
These findings raise several interesting possiblities which cannot be discussed
extensively in this brief report concerning the explanation for this inhibitory
phenomenon . However the resultswe have presented, together with data on the
H-2 requirements for killing in the LCM, ectromelia, hapten-derivatized, and
allogeneic systems, and also reports of chemical, immunologic, and even physi-
cal correspondence between H-2 and tumor antigens favor, in our opinion, the
hypothesis that the particular TAA best able to elicit CTL responses may
represent altered or modified H-2 antigens . These modified H-2 antigens may
coexist in the membrane with unmodified H-2, their respective concentrations
held by an unknown mechanism to a constant total, but variable ratio, which is
alterable by conditions of tumor growth . The reciprocal relationship between
changes in amount ofH-2 and tumor antigen on tumor cells passaged in vivo vs .
in vitro for prolonged times is consistent with this interpretation (11) . Whatever
the actual relationship, this concept of tumor antigen-H-2 antigen similarity
raises important questions about the function of H-2 antigens, perhaps in
immune surveillance, and potential explanations for the adaptive advantage of
maintaining the large number of H-2-reactive T-lymphocytes present in unim-
munized animals.
Received for publication 14 July 1975 .
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